Emily Tarco

Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation

Yan Xing, Nancy U. Lin, Matthew Maurer et al. · Breast Cancer Research · 2019 · 225 citations · Full text

Biomarkers of Response to Akt Inhibitor MK-2206 in Breast Cancer

Takafumi Sangai, Argun Akçakanat, Huiqin Chen et al. · Clinical Cancer Research · 2012 · 157 citations

Open-label randomized clinical trial of standard neoadjuvant chemotherapy with paclitaxel followed by FEC versus the combination of paclitaxel and everolimus followed by FEC in women with triple receptor-negative breast cancer

Ana M. González-Angulo, Argun Akçakanat, S. Liu et al. · Annals of Oncology · 2014 · 103 citations · Full text

Breast Oncology, Medicine, Standard Neoadjuvant Chemotherapy +5

Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a Tertiary Care Facility Increases HER2 Immunohistochemistry and Fluorescence In Situ Hybridization Concordance and Decreases the Number of Inconclusive Cases

Lavinia P. Middleton, Kathy M. Price, Pamela Puig et al. · Archives of Pathology & Laboratory Medicine · 2009 · 97 citations

Implementation of American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Recommendations in a tertiary care facility increases HER2 immunohistochemistry and fluorescence in situ hybridization concordance and decreases the number of inconclusive cases.

Lavinia P. Middleton, Kathy M. Price, Pamela Puig et al. · PubMed · 2009 · 90 citations